115 related articles for article (PubMed ID: 30636711)
1. DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III.
Svanvik T; Strömberg U; Holmberg E; Marcickiewicz J; Sundfeldt K
Int J Gynecol Cancer; 2019 Feb; 29(2):305-311. PubMed ID: 30636711
[TBL] [Abstract][Full Text] [Related]
2. Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study.
Green RW; Engblom S; Baldetorp B; Hartman L; Måsbäck A; Bjurberg M
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1064-73. PubMed ID: 26123703
[TBL] [Abstract][Full Text] [Related]
3. Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma.
Patthey A; Boman K; Tavelin B; Lindquist D; Lundin E; Hultdin M
Acta Oncol; 2021 Sep; 60(9):1218-1224. PubMed ID: 34156893
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of DNA ploidy in non-endometrioid, high-risk endometrial carcinomas.
Sorbe B
Oncol Lett; 2016 Mar; 11(3):2283-2289. PubMed ID: 26998163
[TBL] [Abstract][Full Text] [Related]
5. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
6. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
7. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma.
Santala M; Talvensaari-Mattila A
Anticancer Res; 2003; 23(6D):5191-6. PubMed ID: 14981988
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
9. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Pisani AL; Barbuto DA; Chen D; Ramos L; Lagasse LD; Karlan BY
Obstet Gynecol; 1995 May; 85(5 Pt 1):729-34. PubMed ID: 7724103
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in surgical stage I endometrial carcinoma.
Lundgren C; Auer G; Frankendal B; Nilsson B; Nordström B
Acta Oncol; 2004; 43(1):49-56. PubMed ID: 15068320
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group.
Stålberg K; Kjølhede P; Bjurberg M; Borgfeldt C; Dahm-Kähler P; Falconer H; Holmberg E; Staf C; Tholander B; Åvall-Lundqvist E; Rosenberg P; Högberg T
Int J Cancer; 2017 Jun; 140(12):2693-2700. PubMed ID: 28340503
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of the nuclear proteins p53 and Rb in conjunction with DNA, nuclear morphometry and grading in endometrial carcinoma.
Sorbe B; Risberg B
Int J Gynecol Cancer; 1997 Jan; 7(1):34-41. PubMed ID: 12795802
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
15. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
16. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators.
Lim P; Aquino-Parsons CF; Wong F; Dupuis B; Phillips D; Zhou C; Gilks CB
Gynecol Oncol; 1999 May; 73(2):191-5. PubMed ID: 10329033
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
18. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.
Baak JP; Snijders W; van Diermen B; van Diest PJ; Diepenhorst FW; Benraadt J
J Clin Oncol; 2003 Nov; 21(22):4214-21. PubMed ID: 14615450
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
20. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases.
Blom R; Malmström H; Guerrieri C
Int J Gynecol Cancer; 1999 Mar; 9(2):98-104. PubMed ID: 11240749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
